Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXE408 in Primary Visceral Leishmaniasis
NCT05593666Phase 2Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LXE408 in visceral leishmaniasis (VL) (3 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Proportion of patients with initial cure at 28 days. Started Dec 2022; status: completed.
02
Drugs
LXE408
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT05593666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593666.